
86-10-08 16:59



T0000027

8 OCTOBER 1986

URBENT - PLEASE PASS THIS TELEX IMMEDIATELY TO MR C R BISHOP

THIS IS THE STATEMENT WHICH WE PROPOSE TO PROVIDE TO THE CLOSED BUSINESS MEETING TOMORROW.

'WITH IMMEDIATE EFFECT ARMOUR PHARMACEUTICAL COMPANY LIMITED HAS WITHDRAWN ITS FACTORATE PRODUCTS FROM THE U.K. MARKET.

THE COMPANY HAS RELINGUISHED RELEVANT PRODUCT LICENCES.

THIS ACTION FOLLOWS CONSULTATION WITH THE DHSS AFTER NOTIFICATION ON SEPTEMBER 29, 1986 BY A U.K. PHYSICIAN OF TWO CASES OF SERO-CONVERSION TO HIV ANTIBODY POSITIVE, ASSOCIATED WITH THE USE OF FACTORATE.

BOTH HAEMOPHILIACS HAD FOR SOME MONTHS BEEN TREATED WITH HEAT TREATED FACTORATE WHICH WAS MANUFACTURED FROM PLASMA COLLECTED BEFORE THE BENERAL AVAILABILITY OF THE HIV ASNTIBODY SCREENING TEST.

ARMOUR WITHDREW FOR EXCHANGE ANY RESIDUAL STOCKS OF FACTORATE FROM NON-SCREENED DONORS EARLIER THIS YEAR. THE CURRENT DECISION WAS MADE EVEN THOUGH THE MATERIAL USED IN THE REPORTED CASES WAS NOT THAT CURRENTLY ON THE MARKET, I.E. NOT DONOR SCREENED.

ARMOUR INTEND TO SUSTAIN THEIR INVOLKVEMENT IN THE PROVISION OF PRODUCTS FOR THE MANAGEMENT OF HAEMOPHILIACS KAND WILL DO ALL WE CAN TO MINIMISE ANY ADVERSE EFFECTS OF THIS PRODUCT WITHDRAWAL.

REPRESENTATIVES OF ARMOUR PHARMACEUTICAL COMPANY LIMITED WILL BE PRESENT DURING TOMORROW'S SYMPOSIUM AND ARE AVAILABLE TO ANSWER QUESTIONS TABLED IN ADVANCE AT THIS CLOSED BUSINESS MEETING.'

REGARDS.

R. B. CHRISTIE &
GRO-C GEORGE G
RORER G

ARMOUR003127